Table 6
Clinical characteristics of diabetic patients with and without progression of retinopathy after phacoemulsification during 1 year follow up study
| No progression | Progression | Differences between groups | |
|---|---|---|---|
| No of eyes (%) | 41 (79%) | 11 (21%) | |
| Age (years) | 73 (53–86) | 75 (49–83) | |
| Male/female | 17/24 | 3/8 | |
| Type 1/type 2 | 5/36 | 1/10 | |
| Insulin treatment | 29 | 8 | |
| Duration of diabetes (years) | 19 (5–55) | 14 (8–31) | |
| Final visual acuity | 0.8 (0.1–1.0) | 0.65 (0.1–1.0) | |
| CSMO at baseline | 12 | 5 | |
| Postop CSMO, new cases | — | 2 | p<0.05* |
| Angiographic CMO at baseline | 6 | 2 | |
| Indication for laser treatment at baseline | 21 | 10 | p<0.05* |
-
CSMO = clinically significant macular oedema; CMO = cystoid macular oedema; baseline = 1 week after surgery.
-
↵Values are given as median (range); *significant difference between groups (Fisher exact test, p<0.05).
